Table 2:
Primary and secondary outcomes based on HBP* and CBP** measured at end-point in
116 obese patients with type 2 diabetes mellitus.
Outcome |
Patient
status: HBP* at end-point in 116 obese patients |
Patient
status: CBP** at end-point in 116 obese patients |
||||||
Hypertension |
Normotension |
Hazard ratio |
P |
Hypertension |
Normotension |
Hazard ratio |
P |
|
(n
= 40) |
(n
= 76) |
(95% CI) |
|
(n
= 54) |
(n
= 62) |
(95%
CI) |
||
Primary outcome |
||||||||
Death |
15 |
10 |
3.4 (1.8-9.9) |
0.001 |
13 |
11 |
1.3 (0.6-3.0) |
0.4904 |
Secondary outcome |
||||||||
Microvascular complications |
31 |
40 |
2.0 (1.7-4.9) |
0.001 |
34 |
37 |
0.9 (0.5-1.7) |
0.7110 |
Macrovascular complications |
16 |
9 |
3.3 (1.6-8.2) |
0.0024 |
13 |
12 |
1.2 (0.6-2.7) |
0.5810 |
The obesity was defined by as the definition of the
criteria of Japan Society for the Study of Obesity. Body mass Index (BMI) with ≧ 25.0 kg/m2 was
defined as obesity. The 400 patients in each group were classified as having
obesity and hypertension or normotension according to values of blood pressure
as same threshold of normotension with less than 130 mmHg of systolic blood
pressure measured in the home (HBP*) and in the clinic (CBP**) at end-point,
respectively. Differences in primary and secondary outcomes for events between
obese patients with hypertension and normotension measured at end-point in each
group were assessed using survival curves from the Kaplan-Meier method, and
comparisons were analyzed using hazard ratio by the log-rank test. CI,
confidence interval. Two-tailed values of P < 0.05 were defined as
statistically significant.